Next Science Limited

Equities

NXS

AU0000041329

Pharmaceuticals

Delayed Australian S.E. 01:09:19 2024-04-19 am EDT 5-day change 1st Jan Change
0.435 AUD -7.45% Intraday chart for Next Science Limited +27.94% +27.94%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Study Showing Benefit from Next Science's XPERIENCE Now Published in Scientific Journal MT
Next Science's BLASTX Found to be Efficacious in Treating Pressure Ulcers With Therapy, Says Study MT
Next Science Limited Announces Dan Spira, Non-Executive Director, Not Be Seeking Re-Election CI
Next Science's Loss Widens in 2023 Despite 89% Revenue Growth; Shares Down 7% MT
Next Science Limited Provides Revenue Guidance for the Fiscal Year 2024 CI
Transcript : Next Science Limited, 2023 Earnings Call, Feb 28, 2024
Next Science Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Next Science Limited - Shareholder/Analyst Call
Next Science Limited Announces the Appointment of Katherine Ostin as Independent Non-Executive Director CI
Transcript : Next Science Limited, H1 2023 Earnings Call, Aug 31, 2023
Next Science Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Next Science Limited Announces Board Changes CI
Next Science Limited Announces Change of Registered Office CI
Next Science Limited Appoints Marc Zimmerman as Chief Financial Officer CI
Next Science Limited Announces Retirement of Bruce Hancox as Non-Executive Director CI
Next Science Limited Commercialising Its Proprietary Xbiotm Suite of Products CI
Next Science Appoints Managing Director and CEO; Shares Climb 4% MT
Next Science Limited Announces Executive Changes CI
Next Science Limited Announces Executive Changes CI
Transcript : Next Science Limited - Shareholder/Analyst Call
Next Science Limited(ASX:NXS) dropped from S&P/ASX Emerging Companies Index CI
Transcript : Next Science Limited, 2022 Earnings Call, Feb 28, 2023
Next Science Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Transcript : Next Science Limited - Shareholder/Analyst Call
Next Science Secures AU$10 Million in Convertible Notes; Shares Down 4% MT
Chart Next Science Limited
More charts
Next Science Limited is an Australia-based medical technology company. The Company’s primary focus is on the development and commercialization of its proprietary XBIO technology to reduce the impact of biofilm-based infections on human health. XBIO is a non-toxic technology with an efficacy in eradicating both biofilm-based and free-floating bacteria. The Company’s products include XPERIENCE, Blast X, SurgX and Bactisure. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SurgX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel with sustained effectiveness for up to five days. BLASTX Antimicrobial Wound Gel provides wound management by maintaining a moist wound environment, which is conducive to wound healing.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.3027 USD
Average target price
0.2415 USD
Spread / Average Target
-20.21%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. NXS Stock
  4. News Next Science Limited
  5. Next Science's Collagen Products Secure Medicare Accreditation in the US; Shares Jump 8%